AI Insight
This review compares two spinal cord stimulation approaches for motor recovery after spinal cord injury: epidural SCS, which is surgically implanted, and transcutaneous SCS, which is applied through the skin. The analysis finds these techniques serve distinct therapeutic purposes, with epidural SCS functioning as an immediate assistive device that restores muscle activity within one week and works for all injury severities, while transcutaneous SCS acts as a longer-term therapeutic intervention requiring up to 18 weeks of treatment and primarily benefiting patients with incomplete motor injuries. Both approaches have demonstrated effectiveness when combined with rehabilitation, but lack clear clinical guidelines for selecting between them.
Why it matters
These findings provide critical guidance for clinicians and patients in selecting appropriate spinal cord stimulation therapy based on injury severity, treatment goals, and desired timeframe. By clarifying the distinct roles of each approach, this analysis could accelerate the adoption of these promising neurostimulation technologies into standard clinical practice for spinal cord injury rehabilitation.
Understand the Science
⚠️ Preprint – Noch nicht peer-reviewed
Dieser Artikel wurde noch nicht von unabhängigen Experten begutachtet. Die Ergebnisse sind vorläufig und sollten mit Vorsicht interpretiert werden.
Spinal cord injury (SCI) is a devastating neurological injury that results in the profound loss of voluntary motor function and marked reduction in quality of life. Rehabilitation remains as the standard of care for recovery after SCI; however, it often falls short in recovering meaningful motor function. Spinal cord stimulation (SCS) has emerged as a promising neurostimulation approach to fill this gap and recover lost voluntary motor function. Two main approaches of SCS have been designed and implemented for human use: epidural and transcutaneous SCS. Over the last two decades, several clinical studies have shown convincing evidence that both epidural and transcutaneous SCS can be used in conjunction with rehabilitation to improve motor function of individuals after SCI. Yet fundamental clinical questions remain unanswered: when should clinicians choose epidural or transcutaneous SCS, which technique provides the most durable outcomes, and for whom is each therapy best? Without these answers, widespread and meaningful adoption of either approach into clinical practice will remain limited. To address these questions, in this Review, we define the distinct therapeutic goals, intended use cases, clinical parameters, and responder profiles for both epidural and transcutaneous SCS to guide their eventual adoption into clinical practice. We found that indeed epidural and transcutaneous SCS serve distinct therapeutic roles. Epidural SCS is designed as an assistive therapy that can restore muscle activity and single joint movements immediately within one week of implantation, while transcutaneous SCS is designed as a long-term therapeutic device with cumulative functional gains observed over treatment periods of up to 18 weeks. Lastly, epidural SCS produced benefits for all participants (AIS A-D) despite the extent of their injury, while transcutaneous SCS only consistently benefits individuals with incomplete motor injuries (AIS C-D).